[go: up one dir, main page]

BR9810378A - Compound, use of the same, pharmaceutical composition, and, processes of treating type i or type ii diabetes, of treating hyperglycemia, and of decreasing blood glucose in a mammal - Google Patents

Compound, use of the same, pharmaceutical composition, and, processes of treating type i or type ii diabetes, of treating hyperglycemia, and of decreasing blood glucose in a mammal

Info

Publication number
BR9810378A
BR9810378A BR9810378-4A BR9810378A BR9810378A BR 9810378 A BR9810378 A BR 9810378A BR 9810378 A BR9810378 A BR 9810378A BR 9810378 A BR9810378 A BR 9810378A
Authority
BR
Brazil
Prior art keywords
type
treating
processes
compound
pharmaceutical composition
Prior art date
Application number
BR9810378-4A
Other languages
Portuguese (pt)
Inventor
Anthony Ling
Vlad Gregor
Javier Gonzales
Yufeng Hong
Dan Kiel
Atsuo Kuki
Shenghua Shi
Lars Naerum
Peter Madsen
Christian Sams
Jesper Lau
Michael Bruno Plewe
Jun Feng
Min Teng
Michael David Johnson
Kimberly Ann Teston
Ulla Grove
Lotte Bjerre Knudsen
Original Assignee
Novo Nordisk As
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Agouron Pharma filed Critical Novo Nordisk As
Publication of BR9810378A publication Critical patent/BR9810378A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C07C255/29—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups and acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/45—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms doubly-bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"COMPOSTO, USO DO MESMO, COMPOSIçãO FARMACêUTICA, E, PROCESSOS DE TRATAR A DIABETE DO TIPO I OU DO TIPO II, DE TRATAR A HIPERGLICEMIA, E DE DIMINUIR A GLICOSE DO SANGUE EM UM MAMìFERO". Compostos não peptídicos que compreendem um motivo central de hidrazida e processos para a sua síntese. Os compostos atuam para antagonizar a ação do hormónio peptídico glucagon."COMPOUND, USE OF THE SAME, PHARMACEUTICAL COMPOSITION, AND, PROCESSES OF TREATING DIABETES OF TYPE I OR TYPE II, OF TREATING HYPERGLYCEMIA, AND OF REDUCING BLOOD GLUCOSIS IN A MAMMALIAN". Non-peptide compounds that comprise a central hydrazide motif and processes for its synthesis. The compounds act to antagonize the action of the peptide hormone glucagon.

BR9810378-4A 1997-07-01 1998-06-30 Compound, use of the same, pharmaceutical composition, and, processes of treating type i or type ii diabetes, of treating hyperglycemia, and of decreasing blood glucose in a mammal BR9810378A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88678597A 1997-07-01 1997-07-01
US3251698A 1998-02-27 1998-02-27
PCT/DK1998/000287 WO1999001423A1 (en) 1997-07-01 1998-06-30 Glucagon antagonists/inverse agonists

Publications (1)

Publication Number Publication Date
BR9810378A true BR9810378A (en) 2000-08-29

Family

ID=26708528

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9810378-4A BR9810378A (en) 1997-07-01 1998-06-30 Compound, use of the same, pharmaceutical composition, and, processes of treating type i or type ii diabetes, of treating hyperglycemia, and of decreasing blood glucose in a mammal

Country Status (11)

Country Link
EP (1) EP0994848A1 (en)
JP (1) JP2003514508A (en)
KR (1) KR20010020590A (en)
CN (1) CN1267281A (en)
AU (1) AU749271B2 (en)
BR (1) BR9810378A (en)
HU (1) HUP0002373A3 (en)
IL (1) IL133377A0 (en)
NO (1) NO996550L (en)
PL (1) PL337781A1 (en)
WO (1) WO1999001423A1 (en)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP2002534512A (en) * 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ Non-peptide GLP-1 agonist
US6927214B1 (en) 1999-01-15 2005-08-09 Novo Nordisk A/S Non-peptide GLP-1 agonists
CA2373892A1 (en) * 1999-05-17 2000-11-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
AUPQ262499A0 (en) 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
EP1741447B1 (en) 2000-01-21 2013-09-18 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
WO2001055107A2 (en) * 2000-01-28 2001-08-02 Melacure Therapeutics Ab Aromatic amines and amides acting on the melanocortin receptors
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
BR0111908A (en) * 2000-06-23 2003-04-01 Novo Nordisk As Compound, pharmaceutical composition, use of the compound, and method for treating and / or preventing disorders or diseases
EP1345891A1 (en) * 2000-11-17 2003-09-24 Novo Nordisk A/S Glucagon antagonist/inverse agonist
US6821960B2 (en) 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
WO2002040444A1 (en) * 2000-11-17 2002-05-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU2002223500A1 (en) 2000-11-17 2002-05-27 Novo-Nordisk A/S Glucagon antagonists/inverse agonists
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
JP4563675B2 (en) 2001-10-12 2010-10-13 ハイ・ポイント・ファーマスーティカルズ、エルエルシー Substituted piperidines and their use for the treatment of histamine H3 receptor related diseases
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US20030171411A1 (en) 2001-12-21 2003-09-11 Kodra Janos Tibor Amide derivatives as therapeutic agents
US7514452B2 (en) 2002-02-01 2009-04-07 Dainippon Pharmaceutical Co., Ltd 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
AUPS120902A0 (en) * 2002-03-19 2002-04-18 Unisearch Limited Iron chelators as anti-proliferative agents against tumour cells
WO2003097031A1 (en) * 2002-05-22 2003-11-27 Sanwa Kagaku Kenkyusho Co., Ltd. Obesity preventive or ameliorator containing methylidene hydrazide compound as active ingredient
WO2004002481A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
US7078419B2 (en) 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
EP1615698B1 (en) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
JP2005060385A (en) * 2003-07-31 2005-03-10 Dainippon Pharmaceut Co Ltd Pharmaceutical comprising 2-furancarboxylic acid hydrazide compound
MXPA06003474A (en) 2003-09-30 2006-06-05 Novo Nordisk As Melanocortin receptor agonists.
ATE498404T1 (en) 2003-12-09 2011-03-15 Novo Nordisk As REGULATION OF FOOD PREFERENCE WITH GLP-1 AGONISTS
RU2386622C9 (en) 2004-01-06 2021-04-21 Ново Нордиск А/С Heteroaromatic derivatives of urea and use thereof as glucokinase activators
US8410047B2 (en) 2004-06-11 2013-04-02 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
DE102004030987A1 (en) * 2004-06-26 2006-01-12 Merck Patent Gmbh Ortho-substituted (3-hydroxyphenyl) -acetic acid benzylidene hydrazides
WO2006028970A1 (en) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
WO2006053906A1 (en) 2004-11-22 2006-05-26 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
KR101066882B1 (en) 2004-12-03 2011-09-26 트랜스테크 파르마, 인크. Heteroaromatic Glucokinase Activator
MX2007008331A (en) 2005-01-10 2008-01-14 Cortendo Invest Ab Publ Methods and compositions for treating diabetes, metabolic syndrome and other conditions.
WO2006082205A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
EP1846446B1 (en) 2005-02-02 2013-06-26 Novo Nordisk A/S Insulin derivatives
JP2008533200A (en) 2005-03-21 2008-08-21 メルク エンド カムパニー インコーポレーテッド Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
WO2006104826A2 (en) 2005-03-30 2006-10-05 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007003581A1 (en) 2005-06-30 2007-01-11 Novo Nordisk A/S Phenoxy acetic acids as ppar delta activators
KR101286569B1 (en) 2005-07-04 2013-07-23 하이 포인트 파마슈티칼스, 엘엘씨 Novel medicaments
EP1904467B1 (en) 2005-07-14 2013-05-01 Novo Nordisk A/S Urea glucokinase activators
US8106090B2 (en) 2005-07-20 2012-01-31 Eli Lilly And Company 1-amino linked compounds
EP1931350B2 (en) 2005-09-14 2021-08-04 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
EP1801098A1 (en) 2005-12-16 2007-06-27 Merck Sante 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
US7943613B2 (en) 2005-12-22 2011-05-17 High Point Pharmaceuticals, Llc Compounds, their preparation and use
AU2007229850A1 (en) 2006-03-23 2007-10-04 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
AU2007229492B2 (en) 2006-03-28 2011-11-03 High Point Pharmaceuticals, Llc Benzothiazoles having histamine H3 receptor activity
EP2019585A2 (en) 2006-05-16 2009-02-04 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CN102295606A (en) 2006-05-29 2011-12-28 高点制药有限责任公司 Method of combining 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine,and applicable intermediates thereof its salts and solvates and its use as histamine h3 receptor antagonist
EP2076265A4 (en) 2006-10-02 2010-09-22 Cortendo Invest Ab Ketoconazole enantiomer in humans
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2008059025A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
US7786139B2 (en) 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
EP2099777B1 (en) 2007-01-11 2015-08-12 Novo Nordisk A/S Urea glucokinase activators
JP2010518008A (en) * 2007-02-02 2010-05-27 レッドポイント バイオ コーポレイション TRPM5 inhibitors that modulate insulin and GLP-1 release
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
FR2932481B1 (en) * 2008-06-13 2010-10-08 Sanofi Aventis 4- {2-4-PHENYL-3,6-DIHYDRO-2H-PYRIDIN-1-YL] -2-OXO-ALKYL} -1-PIPERAZIN-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
FR2932482B1 (en) * 2008-06-13 2010-10-08 Sanofi Aventis NOVEL (PHENYL-3,6-DIHYDRO-2H-PYRIDINYL) - (PIPERAZINYL PONTE) -1-ALKANONE DERIVATIVES AND THEIR USE AS P75 INHIBITORS
US20100035932A1 (en) * 2008-08-07 2010-02-11 Schepetkin Igor A Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP5514831B2 (en) 2008-11-17 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション Substituted bicyclic amines for the treatment of diabetes
EA020496B1 (en) 2008-11-21 2014-11-28 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Adamantyl benzamide derivative, pharmaceutical composition containing same and use thereof
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
US8552022B2 (en) 2009-08-13 2013-10-08 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
US8455533B2 (en) 2009-09-02 2013-06-04 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
CA2779088A1 (en) 2009-11-16 2011-05-19 Mellitech [1,5]-diazocin derivatives
FR2953839A1 (en) 2009-12-14 2011-06-17 Sanofi Aventis NOVEL (HETEROCYCLE-PIPERIDINE CONDENSEE) - (PIPERAZINYL) -1ALCANONE OR (HETEROCYCLE-PYRROLIDINE CONDENSED) - (PIPERAZINYL) -1ALCANONE DERIVATIVES AND THEIR USE AS INHIBITORS OF P75
FR2953836B1 (en) 2009-12-14 2012-03-16 Sanofi Aventis NOVEL DERIVATIVES (HETEROCYCLE-TETRAHYDRO-PYRIDINE) - (PIPERAZINYL) -1-ALKANONE AND (HETEROCYCLE-DIHYDRO-PYRROLIDINE) - (PIPERAZINYL) -1-ALKANONE AND THEIR USE AS INHIBITORS OF P75
CA2784799C (en) 2009-12-30 2014-06-10 Shanghai Fochon Pharmaceutical Co Ltd Certain dipeptidyl peptidase inhibtors
CN102834393B (en) 2010-02-03 2015-07-22 武田药品工业株式会社 Apoptosis signal-regulating kinase 1 inhibitors
WO2011103256A1 (en) 2010-02-22 2011-08-25 Merck Sharp & Dohme Corp. Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
EP2539364A1 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptides for treatment of obesity
BR112012021231A2 (en) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh method for enhancing plant yield, plant, construct, use of a construct, method for producing a transgenic plant, collectable parts of a plant, products derived from a plant, use of a nucleic acid and method for producing a product
CN102918055B (en) 2010-03-26 2017-03-29 诺沃—诺迪斯克有限公司 New Glucagon Analogs
EP2571876B1 (en) 2010-05-21 2016-09-07 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
EP2605658B1 (en) 2010-08-18 2016-03-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
WO2012085745A1 (en) 2010-12-23 2012-06-28 Pfizer Inc. Glucagon receptor modulators
EP2673260B1 (en) 2011-02-08 2016-08-17 Pfizer Inc Glucagon receptor modulator
EP2691108A1 (en) 2011-03-28 2014-02-05 Novo Nordisk A/S Novel glucagon analogues
WO2012138845A1 (en) 2011-04-08 2012-10-11 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
CN103687855A (en) 2011-06-02 2014-03-26 英特维特国际股份有限公司 Imidazole derivatives
US9006228B2 (en) 2011-06-16 2015-04-14 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
JP5647379B2 (en) 2011-07-22 2014-12-24 ファイザー・インク Quinolinyl glucagon receptor modulator
AR088161A1 (en) 2011-09-23 2014-05-14 Novo Nordisk As GLUCAGON ANALOGS
EP2760855B1 (en) 2011-09-30 2017-03-15 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes
US9018200B2 (en) 2011-10-24 2015-04-28 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as GPR119 agonists
WO2013068328A1 (en) 2011-11-07 2013-05-16 Intervet International B.V. Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
WO2013068439A1 (en) 2011-11-09 2013-05-16 Intervet International B.V. 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
CA2855249A1 (en) 2011-11-10 2013-05-16 Memorial Sloan-Kettering Cancer Center Treatment of ovarian cancer with benzylidenebenzohydrazides
US9018224B2 (en) 2011-11-15 2015-04-28 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as GPR119 agonists
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
WO2013122920A1 (en) 2012-02-17 2013-08-22 Merck Sharp & Dohme Corp. Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
MX2014012465A (en) 2012-04-16 2015-01-12 Kaneq Pharma Inc Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors.
WO2014018350A1 (en) 2012-07-23 2014-01-30 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-iv inhibitors
US9867869B2 (en) 2012-12-12 2018-01-16 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
SI2986313T1 (en) 2013-04-18 2019-09-30 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US10065945B2 (en) 2014-01-24 2018-09-04 Merck Sharp & Dohme Corp. Isoquinoline derivatives as MGAT2 inhibitors
AU2015247921B2 (en) 2014-04-17 2019-07-11 Merck Sharp & Dohme Llc Sitagliptin tannate complex
CN106536547A (en) 2014-06-04 2017-03-22 诺和诺德股份有限公司 GLP-1/glucagon receptor co-agonists for medical use
EP3209682B1 (en) 2014-10-24 2020-12-30 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and glp-1 receptors
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
EP3233799B1 (en) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands
CN104610156A (en) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 GPR119 agonist containing cyclopropyl hydrazide and cyanobenzene as well as preparation method and application thereof
CN104592121A (en) * 2015-02-13 2015-05-06 佛山市赛维斯医药科技有限公司 Compound containing hydrazide and nitrobenzene structure, as well as preparation method and application thereof
CN104610150A (en) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 Compound containing hydrazide and cyanobenzene structures as well as preparation method and application thereof
CN104610151A (en) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 Compound containing hydrazide and alkoxy benzene structures as well as preparation method and application thereof
CN104557717A (en) * 2015-02-13 2015-04-29 佛山市赛维斯医药科技有限公司 GPR119 hydrazide agonist, preparation method and use thereof
CN104672144A (en) * 2015-02-13 2015-06-03 佛山市赛维斯医药科技有限公司 GPR119 agonist containing cyclopropyl hydrazide and nitrobenzene structures as well as preparation method and application thereof
CN104610157A (en) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 GPR119 agonist containing cyclopropyl hydrazide and halogenated benzene structures and application thereof
CN104592120A (en) * 2015-02-13 2015-05-06 佛山市赛维斯医药科技有限公司 Cyclopropyl hydrazide and methoxybenzene-containing GPR119 agonist as well as preparation method and application thereof
US10800826B2 (en) 2015-10-05 2020-10-13 Merck Sharp & Dohme Corp. Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
CN107151220B (en) * 2015-10-19 2021-07-20 中国医学科学院药物研究所 Phenolic compound containing benzyloxyphenyl, its preparation method and use
EP3496716B1 (en) 2016-08-15 2021-11-03 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
WO2018034917A1 (en) 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
US20200223889A1 (en) 2017-03-15 2020-07-16 Novo Nordisk A/S Bicyclic Compounds Capable of Binding to Melanocortin 4 Receptor
US20210221867A1 (en) 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
WO2020074958A1 (en) 2018-10-12 2020-04-16 Strongbridge Dublin Limited Levoketoconazole for treatment of congenital adrenal hyperplasia and primary aldosteronism
WO2020205688A1 (en) 2019-04-04 2020-10-08 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
CN110229056B (en) * 2019-06-21 2022-11-08 天津科技大学 Novel curcumin analogue and preparation method and application thereof
EP3842060A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled lactam co-agonists of the glucagon and glp-1 receptors
EP3842449A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled olefin co-agonists of the glucagon and glp-1 receptors
EP3842061A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled triazole co-agonists of the glucagon and glp-1 receptors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3859281A (en) * 1971-07-01 1975-01-07 American Home Prod 2,6-dichlorobenzylidenehydrazides
US3836580A (en) * 1971-07-01 1974-09-17 American Home Prod 2,6-dichlorobenzylidenehydrazides
US3746703A (en) * 1971-07-01 1973-07-17 American Home Prod 2,6-dichlorobenzylidenehydrazides
US4334015A (en) * 1979-05-23 1982-06-08 Minnesota Mining And Manufacturing Company Imaging compositions
DE4033808A1 (en) * 1990-04-11 1991-10-17 Bayer Ag NAPHTHALINE DERIVATIVES
JPH04121717A (en) * 1990-09-12 1992-04-22 Fuji Photo Film Co Ltd Novel organic nonlinear optical material and method for converting light wavelength by using this material
JP3529491B2 (en) * 1995-05-16 2004-05-24 旭電化工業株式会社 Thermal recording material
JPH11514651A (en) * 1995-10-31 1999-12-14 メルク エンド カンパニー インコーポレーテッド Substituted pyridylpyrroles, compositions containing said compounds and methods of use

Also Published As

Publication number Publication date
NO996550D0 (en) 1999-12-29
AU7908398A (en) 1999-01-25
PL337781A1 (en) 2000-09-11
WO1999001423A1 (en) 1999-01-14
HUP0002373A2 (en) 2000-10-28
KR20010020590A (en) 2001-03-15
IL133377A0 (en) 2001-04-30
NO996550L (en) 2000-02-29
AU749271B2 (en) 2002-06-20
WO1999001423A8 (en) 1999-05-14
EP0994848A1 (en) 2000-04-26
JP2003514508A (en) 2003-04-15
CN1267281A (en) 2000-09-20
HUP0002373A3 (en) 2000-11-28

Similar Documents

Publication Publication Date Title
BR9810378A (en) Compound, use of the same, pharmaceutical composition, and, processes of treating type i or type ii diabetes, of treating hyperglycemia, and of decreasing blood glucose in a mammal
BR9710452A (en) Anïïlogos of exendin processes for its preparation and medicines containing the same
BR9711098B1 (en) heterocyclic compounds, processes for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
MX9201730A (en) NEW SUBSTITUTED FENILAZACICLOALCANOS ACTING CENTRALLY.
DK179286D0 (en) INSULIN PREPARATION
BR8906988A (en) TETRAPIPTIDIO, PEPTIDE, PHARMACEUTICAL COMPOSITION, PROCESS FOR USE OF PEPTIDE AND REAGENT FOR DIAGNOSIS
BR9813378A (en) Compound, process for preparing the same, and use of it, pharmaceutical composition, and process for preparing the same, and process for effecting immunosuppression
BR9808285A (en) Zinc-free insulin crystals, therapeutic powder formulation, process for preparing zinc-free insulin crystals, use of zinc-free crystals, and process for the treatment of diabetes mellitus
BR0009864A (en) Compound, pharmaceutical composition, methods for the treatment of diseases, for the treatment and / or prevention of conditions mediated by nuclear receptors and for the treatment and / or prevention of diabetes and / or obesity, and, use of a compound
BR0010651A (en) Compound, use of a compound, pharmaceutical composition, and method for the treatment and / or prevention of disorders or diseases mediated by an antagonistic action of glucagon
AR015493A1 (en) CYCLHEXILOS DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THE USE OF THE SAME FOR THE MANUFACTURE OF A USEFUL COMPOSITION TO INHIBIT THE IN VITRO ACTIVITY OF NEURAMINIDASE AND FOR THE TREATMENT OR PROFILAXIS OF INFLUENZA INFLUENZA AND FOR THE PROCESSING AND PROCESSING
BR9607647A (en) Insulin derivative and pharmaceutical composition and process for the treatment of diabetes in a patient in need of this treatment
NO990916L (en) Use of GLP-1 or analogues in the treatment of myocardial infarction
AR010385A1 (en) PROPIOPHENONE-DERIVED COMPOUND, PROCESS FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITION CONTAINING IT AND USE OF SUCH COMPOUND.
EA200100541A1 (en) PHARMACEUTICAL COMPOSITION WITH MODIFIED SURVIVAL OF THE SENSITIZER TO INSULIN AND OTHER ANTI-DIABETIC AGENTS
BRPI9611096B8 (en) A pharmaceutical composition comprising a stable extract of hypericum perforatum l.
PT1131039E (en) USE OF A SUBSTANCE THAT CONNECTS TO THE PERIPHERAL RECEPTOR OF BENZODIAZEPINAS IN THE TREATMENT OF SKIN STRESSES
BR9608835A (en) Process to reduce hyperglycemia and stabilize the level of glucose in serum in humans, synthetic chromic tripicolinate in unit dosage form, and its use.
BRPI0408229A (en) pharmaceutical preparation, methods for preparing a zinc binding ligand, for prolonging the action of an acid stabilized insulin preparation and for treating type 1 or type 2 diabetes, and use of a preparation
IS1565B (en) Process for the preparation of N1-substituted benzimidazole derivatives for therapeutic use
BR9910329A (en) Compound, pharmaceutical composition, process to stimulate the release of growth hormone from a mammal's pituitary, and use of a compound
NO882207L (en) MIXING CRYSTALS OF INSULIN AND INSULIN DERIVATIVES, PREFACE. FOREVER. OF THESE MIXTURE CRYSTALS, PHARMACEUTICAL AGENTS CONTAINING THESE MIXTURE CRYSTALS AND THEIR USE FOR TREATMENT OF DIABETES MELLITUS.
BR0011928A (en) Compound, pharmaceutical composition, use of, a compound and methods for the treatment of diabetic complications, for the treatment or prevention of the development of disease conditions associated with impaired neuronal conduction velocity and diabetic neuropathy
KR950700326A (en) Paratormon fragments, methods for their preparation and pharmaceuticals containing them (PARATHYROID HORMONE FRAGMENTS, THEIR PREPARATION AND MEDICAMENTS CONTAINING THE SAME)
BR9106676A (en) PEPTIDE, PROCESS TO PROMOTE THE RELEASE OF GROWTH HORMONE LEVELS IN ANIMAL, PHARMACEUTICAL COMPOSITION TO PROMOTE THE RELEASE OF GROWTH HORMONE LEVELS IN ANIMALS, USE OF THE COMPOUND AND PROCESS TO PROMOTE THE LIBERATION IN THE ELEVATION BLOOD

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1889 DE 20/03/2007.